OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The role of radioactive Iodine-131 (131I) as a complimentary therapy to surgery in the management of patients with Differentiated Thyroid Cancer (DTC) is well established [1-10]. There is evidence that radioiodine (RAI) therapy is beneficial in terms of prevention of recurrence and lowering of mortality rates in DTC patients [11,12] Doi et al. [12] showed, in their hospital based study, a trend towards improvement in outcome with radioiodine remnant ablation for cancer specific survival.
